Paper Details
- Yuma Yamada (Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University / Laboratory for Innovative Nano-Pharmaceutical Science, Faculty of Pharmaceutical Sciences, Hokkaido University / u-ma@pharm.hokudai.ac.jp)
1) Department of Pediatrics, Graduate School of Medicine, Hokkaido University , 2) Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University , 3) Laboratory for Innovative Nano-Pharmaceutical Science, Faculty of Pharmaceutical Sciences, Hokkaido University , 4) Regenerative Medicine and Cell Therapy Laboratories, Kaneka Corporation, , 5) Laboratory of Molecular and Cellular Medicine, Faculty of Pharmaceutical Sciences, Hokkaido University
Mesenchymal stromal cell transplantation therapy has been widely studied in regenerative medicine for the treatment of various diseases. We previously developed a mitochondria-targeted drug delivery system, termed the MITO-Porter, which enables large-scale production of coenzyme Q10 (CoQ10)-encapsulated carriers. This study aimed to generate mitochondrial-activated amnion-derived mesenchymal stromal cells (AMSCs) by delivering CoQ10 to mitochondria using the MITO-Porter system, with the potential to improve AMSC transplantation outcomes. We treated AMSCs with CoQ10-encapsulated MITO-Porter and evaluated cellular uptake, co-localization with mitochondria, changes in mitochondrial respiratory capacity, and antioxidant capacity. CoQ10-encapsulated MITO-Porter was internalized by AMSCs and co-localized with mitochondria. Treatment of AMSCs with CoQ10-encapsulated MITO-Porter significantly increased the mitochondrial oxygen consumption rate and decreased superoxide levels. Mitochondrial delivery of CoQ10 successfully enhanced the mitochondrial respiratory capacity and antioxidant ability of AMSCs. These mitochondrial-activated AMSCs, newly generated using the MITO-Porter system, represent a promising cell source for improving MSC-based transplantation therapy.
